There were 58 press releases posted in the last 24 hours and 398,379 in the last 365 days.

State Opioid Response Grants

Short Title: SOR
Initial Announcement Back to the Grants Dashboard

Notice of Funding Opportunity (NOFO)

NOFO Number: TI-24-008

Posted on Grants.gov: Thursday, May 02, 2024

Application Due Date: Monday, July 01, 2024

Catalog of Federal Domestic Assistance (CFDA) Number: 93.788

Intergovernmental Review (E.O. 12372):

Public Health System Impact Statement (PHSIS) / Single State Agency Coordination:

Description

The purpose of this program is to address the public health crisis caused by escalating opioid misuse, opioid use disorder (OUD), and opioid-related overdose across the nation. States and territories are expected to use the resources to: (1) increase access to U.S. Food and Drug Administration (FDA)-approved medications for the treatment of opioid use disorder (MOUD); (2) support the continuum of prevention, harm reduction, treatment, and recovery support services for OUD and other concurrent substance use disorders; and (3) support the continuum of care for stimulant misuse and use disorders, including those involving cocaine and methamphetamine.

Eligibility

Eligibility is limited to Single State Agencies (SSAs) and territories.

Award Information

Funding Mechanism: Grant

Anticipated Total Available Funding: $1,480,500,000

Anticipated Number of Awards: Up to 59

Anticipated Award Amount: See Appendix A for estimated award amounts

Length of Project: Up to 3 years

Cost Sharing/Match Required?: No

Annual continuation awards will depend on the availability of funds, progress in meeting project goals and objectives, timely submission of required data and reports, and compliance with all terms and conditions of award.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.